Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream

Clinical and Experimental Dermatology

Volumn 21, Issue 6, 1996, Pages 409-414

  Van Der Vleuten, C J M ^a   De Jong, E M G J ^a   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DITHRANOL; KERATIN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; EPIDERMIS CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; TOPICAL DRUG ADMINISTRATION;

EID: 0030428122     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.1996.tb00143.x     Document Type: Article

References (37)

1. de Jong EM, van de Kerkhof PC. Short contact dithranol treatments of psoriasis, using a novel emulsifying ointment (Hermal AW). Eur J Dermatol 1992; 2: 552-9.
2. Swanbeck G, Liden S. The inhibitory effect of dithranol (anthralin) on DNA synthesis. Acta Derm Venereol Stockh 1966; 46: 228-30.
3. van de Kerkhof PC. Dithranol treatment for psoriasis: after 75 years, still going strong! Eur J Dermatol 1991; 1: 79-88.
4. Hegemann L, Fruchtmann R, van Rooijen LA et al. The antipsoriatic drug, anthralin, inhibits protein kinase C - implications for its mechanism of action. Arch Dermatol Res 1992; 284: 179-83.
5. Anderson R, Lukey PT, Dippenaar U et al. Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation. Br J Dermatol 1987; 117: 405-18.
6. Chang A, Alkemade H, van de Kerkhof PC. Dithranol modulates the leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukoctyes. J Invest Dermatol 1989; 92: 806-8.
7. Schroder JM. Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene production and LTB4-omega oxidation by human neutrophils. J Invest Dermatol 1986; 87: 624-9.
8. Holland DB, Wood EF, Cunliffe WJ, Turner DM. Keratin gene expression during the resolution of psoriatic plaques: effect of dithranol, PUVA, etretinate and hydroxyurea regimes. Br J Dermatol 1989; 120: 9-19.
9. Ros JJ, Van der Meer YG. Preparation, analysis and stability of oil-in-water creams containing dithranol. Eur J Hosp Pharm 1991; 1: 77-84.
10. van Duijnhoven J, Schalkwijk J, Kranenhorg M et al. MON-150, a versatile monoclonal antibody against involucrin: characterization and applications. Arch Dermatol Res 1992; 284: 167-72.
11. Mahrle G, Bonnekoh B, Wevers A, Hegemann L. Anthralin: how does it act and are there more favourable derivatives? Acta Derm Venereol Suppl (Stockh) 1994; 186: 83-4.
12. Wilson PD, Ive FA. Dithrocream in psoriasis. Br J Dermatol 1980; 103: 105-6.
13. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithranol in psoriasis. Preliminary report on penetration and clinical efficacy. Br J Dermatol 1980; 102: 571-3.
14. Young E. Treatment of psoriasis with dithranol cream compared with dithranol paste. Dermatologica 1986; 173: 285-7.
15. de Jong EM, van de Kerkhof PC. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations. Br J Dermatol 1991; 124: 221-9.
16. van der Vleuten CJ, de Jong EM, van der Kerkhof PC. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996; 288: 366-72.
17. Gerritsen MJ, Boezeman JB, van Vlijmen Willems IM, van de Kerkhof PC. The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study. Br J Dermatol 1994; 131: 57-63.
18. Gerritsen MJ, Rulo HF, Van Vlijmen Willems I et al. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study. Br J Dermatol 1993; 128: 666-73.
19. de Jong EM, Ferrier CM, de Zwart AJ et al. Effect of topical treatment with budesonide on parameters of proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9: 185-94.
20. van Vlijmen Willems IM, Chang A, Boezeman JB, van de Kerkhof PC. The immunohistochemical effect of a hydrocolloid occlusive dressing (DuoDERM E) in psoriasis vulgaris. Dermatology 1993; 187: 257-62.
21. Watanabe S, Wagatsuma K, Ichikawa E, Takahashi H. Abnormal distribution of epidermal protein antigens in psoriatic epidermis. J Dermatol 1991; 18: 143-51.
22. Ishida Yamamoto A, Iizuka H. Differences in involucrin immunolabeling within cornified cell envelopes in normal and psoriatic epidermis. J Invest Dermatol 1995; 104: 391-5.
23. Esmann J, Voorhees JJ, Fisher GJ. Increased membrane-associated transglutaminase activity in psoriasis. Biochem Biophys Res Commun 1989; 164: 219-24.
24. Iizuka H, Takahashi H. Psoriasis, involucrin, and protein kinase C. Int J Dermatol 1993; 32: 333-8.
25. Fisher GJ, Tavakkul A, Leach K et al. Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: reduced expression of protein kinase C-beta II in psoriasis. J Invest Dermatol 1993; 101: 553-9.
26. Matsui MS, Chew SL, DeLeo VA. Protein kinase C in normal human epidermal keratinocytes during proliferation and calcium-induced differentiation. J Invest Dermatol 1992; 99: 565-71.
27. Horn F, Marks F, Fisher GJ et al. Decreased protein kinase C activity in psoriatic versus normal epidermis. J Invest Dermatol 1987; 88: 220-2.
28. Dlugosz AA, Yuspa SH. Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C. J Cell Biol 1993; 120: 217-25.
29. Isseroff RR, Stephens LE, Gross JL. Subcellular distribution of protein kinase C/phorbol ester receptors in differentiating mouse keratinocytes. J Cell Physiol 1989; 141: 235-42.
30. Dlugosz AA, Yuspa SH. Protein kinase C regulates keratinocyte transglutaminase (TGK) gene expression in cultured primary mouse epidermal keratinocytes induced to terminally differentiate by calcium. J Invest Dermatol 1994; 102: 409-14.
31. Dlugosz AA, Cheng C, Williams EK et al. Alterations in murine keratinocyte differentiation induced by activated rasHa genes are mediated by protein kinase C-alpha. Cancer Res 1994; 54: 6413-20.
32. Slater SJ, Kelly MB, Taddeo FJ, Larkin JD et al. Direct activation of protein kinase C by 1 alpha,25-dihydroxyvitamin D3. J Biol Chem 1995; 270: 6639-43.
33. Yada Y, Ozeki T, Meguro S, Mori S et al. Signal transduction in the onset of terminal keratinocyte differentiation induced by 1 alpha,25-dihydroxyvitamin D3: role of protein kinase C translocation Biochem Biophys Res Commun 1989; 163: 1517-22.
34. van Erp PE, de Mare S, Rijzewijk JJ, van de Kerkhof PC et al. A sequential double immunoenzymatic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. Histochem J 1989; 21: 343-7.
35. van der Vleuten CJ, Kroot EJA, de Jong EM, van de Kerkhof PC. The immunohistochemical effects of an intermediate dose of ultraviolet B on normal human skin. Arch Dermatol Res 1996; 288: 510-16.
36. Gerritsen MJ, Elbers M, de Jong EM, van de Kerkhof PC. Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the psoriatic plaque, the uninvolved skin of psoriatic patients and in normal healthy skin. J Dermatol Sci 1997 (in press).
37. de Jong EM, van Erp PE, van Vlijmen IM, van de Kerkhof PC. The interrelation between inflammation and epidermal proliferation in normal human skin following epicutaneous application of leukotriene B4; immunohistochemical study. Clin Exp Dermatol 1996; 17: 413-20.